UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 6-K
------------
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
June 13, 2008
------------
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
NOVO ALLE
DK-2880, BAGSVAERD
DENMARK
(Address of principal executive offices)
------------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____________________
TRANSACTION IN OWN SHARES
REDUCTION OF THE SHARE CAPITAL AND STATUS OF HOLDING OF OWN SHARES
(13 JUNE 2008)
At Novo Nordisk's ordinary general meeting on 12 March 2008 it was decided to
reduce the company's B share capital from DKK 539,472,800 to DKK 526,512,800 by
cancellation of part of the company's portfolio of own B shares at a nominal
value of DKK 12,960,000 divided into 12,960,000 B shares of DKK 1.
Today, Novo Nordisk has registered the final implementation of the reduction of
the share capital with the Danish Commerce and Companies Agency and cancelled
nominally DKK 12,960,000 B shares. After the reduction of the share capital, the
company's share capital is nominally DKK 634,000,000, which is divided into an A
share capital of nominally DKK 107,487,200 and a B share capital of nominally
DKK 526,512,800.
HOLDING OF OWN SHARES
In the company's stock exchange announcement no 33/2008 released on 9 June 2008
it was stated that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates
as per 9 June 2008 owned 28,781,920 of its own B shares of DKK 1, corresponding
to a total nominal value of DKK 28,781,920 or 4.5% of the total share capital.
Since 9 June 2008 a total of 192,000 B shares have been repurchased by Novo
Nordisk A/S, and 70 B shares have been disposed of to employees who have
exercised options granted by Novo Nordisk.
Following the cancellation of nominally DKK 12,960,000 (12,960,000 shares) of
the company's own B shares and pursuant to Section 28 of the Danish Securities
Trading Act, it is hereby announced that Novo Nordisk A/S and its wholly-owned
affiliates as per 13 June 2008 own 16,013,850 of its own B shares. This
corresponds to a total nominal value of DKK 16,013,850 B shares or 2.5 % of the
total share capital.
The reduction in the share capital will not affect Novo Nordisk's share
repurchase programme which will continue as previously announced.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 26,300 employees in
80 countries, and markets its products in 179 countries. Novo Nordisk's B shares
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed
on the New York Stock Exchange under the symbol 'NVO'. For more information,
visit novonordisk.com.
Further information:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisk.com
In North America: In North America:
Sean Clements Christian Qvist Frandsen
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com cqfr@novonordisk.com
Stock Exchange Announcement no 35 / 2008
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf of the
undersigned, thereunto duly authorized.
Date: June 13, 2008 NOVO NORDISK A/S
---------------------------------------------------
Lars Rebien Sorensen,
President and Chief Executive Officer